Using approved medicines to break up harmful protein clumps in Alzheimer's
Official title: Repurposing FDA-approved drugs to disrupt tau- and amyloid-associated protein-protein interactions in Alzheimer's disease aggregates
Funded at Central Arkansas Veterans Hlthcare Sys · NIH-11206875 · Data updated 2026-11-12
Testing whether already-approved drugs can disrupt sticky tau and amyloid protein clumps that form in people with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Central Arkansas Veterans Hlthcare Sys NIH-funded |
| Lab location | 1 site (North Little Rock, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2026 |
| NIH project number | 5I01BX006445-02 |
| Project ID | NIH-11206875 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with Alzheimer’s disease, especially those in earlier stages or with evidence of tau and amyloid pathology, would be the most likely candidates for future trials based on this work.
✕Less likely to help
People with non-amyloid/tau causes of dementia or those in very advanced, end-stage Alzheimer’s are unlikely to benefit from these anti-aggregation approaches.
What this research studies
Researchers map how proteins stick together in Alzheimer’s brain tissue to find the exact contact points that hold toxic clumps together. They use computer screening to find FDA-approved drugs that can fit into those protein interfaces and block them. Promising hits are tested in human cells and simple animal models, and the top candidates will be tried next in mice. The goal is to move faster toward treatments because these drugs are already approved for other uses.
Why it matters
Potential benefit: If successful, this could reduce or clear harmful protein aggregates and slow the progression of memory and thinking problems in Alzheimer's patients.
How similar studies have gone: Laboratory and animal studies of drug repurposing and anti-aggregation approaches have shown promise, but clinical success in people has been limited so far.
Where this research is happening
-
Central Arkansas Veterans Hlthcare Sys
North Little Rock, United States Active
Researchers
- Principal investigator: Shmookler Reis, Robert Joseph — Central Arkansas Veterans Hlthcare Sys
- Study coordinator: Shmookler Reis, Robert Joseph
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.